Figure S1



Number at risk:

SRS+ipilimumab	45	32	8	3	1
SRS+nivolumab.	35	29	14	8	3



Number at risk:

SRS+ipilimumab	45	30	7	3	1
SRS+nivolumab.	35	30	13	7	3